PXPeng Xie

Peng Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peng Xie has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaolin Li

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China

    8 shared publications
  • Wenjie Tang

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China

    6 shared publications
  • Jinming Yu

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    4 shared publications
  • Wanqi Zhu

    Department of Science and Education, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China

    4 shared publications
  • Xindong Sun

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    4 shared publications
  • Bing Zou

    Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

    3 shared publications

Latest Publications

  • Open Access

    Immunometabolic reprogramming reshapes the tumor microenvironment in PARPi-resistant ovarian cancer towards predictive, preventive, and personalized medicine approaches

    by Yanjun Zhang, Arshad Ali, Xiaoxia Feng, Peng Xie, Xianquan Zhan, Na Li

    Ovarian cancer is a highly lethal gynecologic malignancy that affects women worldwide. Its clinical symptoms are often insidious, and its recurrence rate remains high. Patient prognosis is severely limited by these factors. Poly(ADP-ribose) polymerase inhibitors (PARPi) have achieved remarkable clinical efficacy and are commonly used for treating ovarian cancer with homologous recombination deficiency by inducing synthetic lethality. However, acquired resistance remains a major clinical challenge in modern practice. Genomic alterations and the restoration of DNA repair capacity have been the primary focus of traditional research on resistance mechanisms. Recent studies have pointed to the tumor microenvironment (TME) as a key player, and its immunometabolic reprogramming has been recognized as crucial for driving PARPi resistance and enabling tumor immune evasion. However, the strength of this evidence varies substantially across experimental contexts. This review therefore distinguishes acute or ongoing effects of PARPi exposure from phenotypes associated with established acquired resistance and explicitly separates direct evidence in ovarian cancer from mechanistic observations extrapolated from other tumor types. The dynamic immunometabolic changes seen in the TME of PARPi-resistant ovarian cancer are reviewed. It highlights context-dependent metabolic plasticity involving glycolysis and oxidative phosphorylation (OXPHOS), and discusses how nutrient competition and metabolites such as lactate and acetyl-CoA may influence immune cell function. Specifically, this review explores metabolic exhaustion of effector T cells and natural killer (NK) cells, as well as metabolically driven mechanisms underlying heterogeneous tumor-associated macrophage (TAM) states, rather than a simple M1-to-M2 switch. Finally, it introduces the emerging Predictive, Preventive, and Personalized Medicine (PPPM/3PM) paradigm and discusses how early metabolic profiling, precise immunometabolic modulation, and multi-target combinatorial interventions may reshape the tumor immune microenvironment and potentially overcome PARPi resistance, although most proposed interventions still require prospective clinical validation.

  • Open Access

    Coronavirus disease 2019 infection reduces EGFR ‐ TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

    by Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, et al.

    Coronavirus disease 2019 (COVID‐19) remains a global health threat, particularly for patients with cancer, who experience greater susceptibility and worse outcomes. Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) is standard first‐line therapy for advanced EGFR‐mutated non‐small cell lung carcinoma (NSCLC). However, the impact of COVID‐19 on TKI efficacy remains unclear. This multicenter retrospective study included patients with stage IV EGFR‐mutated NSCLC who received first‐line EGFR‐TKI treatment at four Chinese hospitals. Leveraging China's policy change (December 2022), we compared a pre‐pandemic COVID‐19‐negative cohort (January 2019–November 2022) with a COVID‐19‐positive cohort (January–June 2023). After 1:1 propensity score matching (PSM), Kaplan–Meier and Cox regression analyses evaluated progression‐free survival (PFS) and prognostic factors. Among 711 patients (median follow‐up, 37.90 months), the COVID‐19‐negative group had significantly longer median PFS (18.17 vs. 12.89 months; p = .001). After PSM, we analyzed 426 well‐matched patients (213/cohort). Before and after matching, COVID‐19‐negative patients exhibited better PFS with all EGFR‐TKI generations (unmatched: p 1st <.001, p 2nd = .030, and p 3rd = .001; matched: p 1st <.001, p 2nd = .049, and p 3rd = .015). COVID‐19 infection worsened outcomes in both monotherapy and combination therapy. Multivariable analysis identified COVID‐19 infection as an independent predictor of worse PFS (hazard ratio 1.650, 95% confidence interval: 1.286–2.116; p < .001). Adenocarcinoma, ≤3 metastatic organs, smoking index >570, concurrent systemic therapy, and third‐generation TKI were also prognostic. COVID‐19 infection markedly reduces EGFR‐TKI efficacy in patients with advanced NSCLC, warranting closer monitoring during and after infection and supporting adaptive management strategies.

  • Open Access

    Sodium glycididazole combined with definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: A multicenter randomized clinical trial

    by Xiaoling Li, Hanxi Zhao, Peng Xie, Wanqi Zhu, Liping Liu, Peipei Wu, Yanxing Sheng, Chuandong Wang, Yipeng Song, Xiangjiao Meng, et al.

    Purpose: To evaluate the efficacy and safety of the radiosensitizer‐sodium glycididazole (CMNa) combined with definitive concurrent chemoradiotherapy (CCRT) versus CCRT alone in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: Patients were enrolled and randomly assigned to receive CMNa plus CCRT (CMNa group) or CCRT alone (control group). CMNa (800 mg/m 2 ) was administered three times per week during radiotherapy (1.8‐2.0 Gy per fraction, total dose of 59.4‐60.0 Gy). The primary endpoint was the objective response rate (ORR) and the secondary endpoint was the incidence of adverse events. Results: Sixty‐six patients with ESCC were recruited from six medical centers between 2016 and 2018. The ORRs in the CMNa and control groups were 90.32% and 68.57%, respectively ( χ 2 = 4.925, p = 0.0265). The proportions of patients with a complete response were 8/31 (25.81%) and 8/35 (22.86%) in the CMNa and control groups, respectively. The combination of CMNa and CCRT did not increase the incidence of acute or late adverse effects. Conclusion: CMNa combined with CCRT improved the ORR in patients with ESCC compared with CCRT alone without increasing treatment‐related toxicity. Trial Registration: The protocol was registered at Clinicaltrials.gov ( www.clinicaltrials.gov ) (Clinical Trials ID: NCT02721563). Study Registration Date: March 29, 2016.

  • Open Access

    Prognostic Value of Ferroptosis-Immunity-Related Signature Genes in Cervical Cancer Radiotherapy Resistance and Risk Modeling

    by Xianzhen Zhang, Aihua Li, Wanqi Zhu, Qiufen Guo, Qian Wu, Hong Zhao, Yunbei Yu, Peng Xie, Xiaolin Li

    Introduction: The aim of this study was to clarify the genome of ferroptosis in the genes involved in radiotherapy resistance and regulation of tumor immune microenvironment by multigene analysis of cervical cancer (CC) patients. Methods: Different radiation sensitivity samples from CC patients were collected for RNA sequencing. Differentially expressed genes (DEGs) between the RNA dataset and the GSE9750 dataset were considered as radiotherapy-DEGs. The intersection genes of radiotherapy-DEGs with ferroptosis-related genes (FRGs) and the intersection genes of radiotherapy-DEGs with immune-related genes (IRGs) were labeled as FRGs-IRGs-DEGs (FIGs). A risk model was established by prognostic genes selected from FIGs by univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) analysis. The results were further validated using samples from CC tissue samples. Results: The 329 DEGs related to CC radiotherapy were identified. LSAAO analysis was utilized to identify five prognostic genes (CALCRL, UCHL1, GNRH1, ACVRL1, and MUC1) from six candidate prognosis genes and construct a risk model. The risk model demonstrated favorable effectiveness in predicting outcomes at 1, 3, and 5 years, as evidenced by ROC curves. Univariate and multivariate Cox regression analysis demonstrated that CALCRL, GNRH1, and MUC1 were independent prognostic factors. The results of functional similarity analysis showed that CALCRL, UCHL1, ACVRL1 and MUC1 had high average functional similarity. The results of PCR and IHC showed the same trend with the results above. Discussion: A novel prognostic model related to ferroptosis and immune microenvironment in CC radiotherapy was developed and validated, providing valuable guidance for personalized anti-cancer therapy.


  • EP04.01-03 Advancing Malignancy Risk Stratification for Early-Stage Cancers in Lung Nodules by Combined Imaging and Electrical Impedance Analysis

    by D. Yang, C. Gu, Y. Gu, X. Zhang, D. Ge, Y. Zhang, N. Wang, X. Zheng, H. Wang, L. Yang, et al.

  • Open Access

    Editorial: The role of maintenance therapy (immunotherapy, targeted therapy, etc) in cancer control and biologic behavior of recurrent/metastatic cervical cancer

    by Xiaolin Li, Xianzheng Zhang, Aihua Li, Peng Xie

    Editorial: The role of maintenance therapy (immunotherapy, targeted therapy, etc) in cancer control and biologic behavior of recurrent/metastatic cervical cancer


  • Open Access

    Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: a phase I clinical trial

    by Jingjing Xie, Li Jia, Peng Xie, Xiaoyan Yin, Wanqi Zhu, Hong Zhao, Xin Wang, Xiangjiao Meng, Ligang Xing, Hanxi Zhao, et al.

    To evaluate the safety and effectiveness of epigallocatechin-3-gallate (EGCG) solution treating the acute severe dermatitis in patients receiving radiotherapy. This phase I research enrolled patients with thoracic cancer receiving radiotherapy at Shandong Cancer Hospital and Institute in Shandong, China. EGCG solution was sprayed to the radiation field when grade III radiation-induced dermatitis (RID) first appearance. EGCG concentration escalated from 660 to 2574 μmol/L using modified-Fibonacci dose-escalation. RID and related symptoms were followed up every day. Between March 2021 and November 2021, 19 patients were enrolled in this phase I research. The median dose of grade III RID first observation was 44 Gy (30.6–52 Gy). As the EGCG treatment was performed continuously, all these grade III RID reactions were significantly decreased to grade I or grade II RID at three days after use of EGCG (p < 0.001). Significant relief can be observed in burning sensation (p < 0.001), tractive sensation (p < 0.001), tenderness (p < 0.001), erythema (p < 0.001), itching (p < 0.001) and pain (p < 0.001) after 15 days of EGCG treatment. No radiation therapy delay or interruption for all 19 patients. No adverse events were observed and reported associated with EGCG. The highest dose of this Phase I trial (2574 μmol/L) was recommended for continuous Phase II trial for further evaluation. In this phase I clinical research, use of EGCG solution is safe and can significantly relief grade III RID in patients receiving radiotherapy. Thus, EGCG might be a new choice for acute sever RID.Trial Registration: ClinicalTrials.gov Identifier: NCT02580279 (Full date of first registration: 12/2014).


  • Open Access

    Primary tumor location in lung cancer: the evaluation and administration

    by Xueqi Xie, Xiaolin Li, Wenjie Tang, Peng Xie, Xuefen Tan

    Lung cancer continues to be the leading cause of cancer-related death in the world, which is classically subgrouped into two major histological types: Non-small cell lung cancer (NSCLC) (85% of patients) and small-cell lung cancer (SCLC) (15%). Tumor location has been reported to be associated with the prognosis of various solid tumors. Several types of cancer often occur in a specific region and are more prone to spread to predilection locations, including colorectal cancer, prostate cancer, gastric cancer, ovarian cancer, cervical cancer, bladder cancer, lung tumor, and so on. Besides, tumor location is also considered as a risk factor for lung neoplasm with chronic obstructive pulmonary disease/emphysema. Additionally, the primary lung cancer location is associated with specific lymph node metastasis. And the recent analysis has shown that the primary location may affect metastasis pattern in metastatic NSCLC based on a large population. Numerous studies have enrolled the “location” factor in the risk model. Anatomy location and lobe-specific location are both important in prognosis. Therefore, it is important for us to clarify the characteristics about tumor location according to various definitions. However, the inconsistent definitions about tumor location among different articles are controversial. It is also a significant guidance in multimode therapy in the present time. In this review, we mainly aim to provide a new insight about tumor location, including anatomy, clinicopathology, and prognosis in patients with lung neoplasm.


  • Open Access

    A novel nomogram containing acute radiation esophagitis predicting radiation pneumonitis in thoracic cancer receiving radiotherapy

    by Wenjie Tang, Xiaolin Li, Haining Yu, Xiaoyang Yin, Bing Zou, Tingting Zhang, Jinlong Chen, Xindong Sun, Naifu Liu, Jinming Yu, et al.

    Background: Radiation-induced pneumonitis (RP) is a non-negligible and sometimes life-threatening complication among patients with thoracic radiation. We initially aimed to ascertain the predictive value of acute radiation-induced esophagitis (SARE, grade ≥ 2) to symptomatic RP (SRP, grade ≥ 2) among thoracic cancer patients receiving radiotherapy. Based on that, we established a novel nomogram model to provide individualized risk assessment for SRP. Methods: Thoracic cancer patients who were treated with thoracic radiation from Jan 2018 to Jan 2019 in Shandong Cancer Hospital and Institute were enrolled prospectively. All patients were followed up during and after radiotherapy (RT) to observe the development of esophagitis as well as pneumonitis. Variables were analyzed by univariate and multivariate analysis using the logistic regression model, and a nomogram model was established to predict SRP by “R” version 3.6.0. Results: A total of 123 patients were enrolled (64 esophageal cancer, 57 lung cancer and 2 mediastinal cancer) in this study prospectively. RP grades of 0, 1, 2, 3, 4 and 5 occurred in 29, 57, 31, 0, 3 and 3 patients, respectively. SRP appeared in 37 patients (30.1%). In univariate analysis, SARE was shown to be a significant predictive factor for SRP (P < 0.001), with the sensitivity 91.9% and the negative predictive value 93.5%. The incidence of SRP in different grades of ARE were as follows: Grade 0–1: 6.5%; Grade 2: 36.9%; Grade 3: 80.0%; Grade 4: 100%. Besides that, the dosimetric factors considering total lung mean dose, total lung V5, V20, ipsilateral lung mean dose, ipsilateral lung V5, and mean esophagus dose were correlated with SRP (all P < 0.05) by univariate analysis. The incidence of SRP was significantly higher in patients whose symptoms of RP appeared early. SARE, mean esophagus dose and ipsilateral mean lung dose were still significant in multivariate analysis, and they were included to build a predictive nomogram model for SRP. Conclusions: As an early index that can reflect the tissue’s radiosensitivity visually, SARE can be used as a predictor for SRP in patients receiving thoracic radiation. And the nomogram containing SARE may be fully applied in future’s clinical work.